Larvol Veri

TNFRSF8 expression TNFRSF8 expression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	belinostat Sensitive: A1 - Approval belinostat Sensitive : A1
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	brentuximab vedotin Sensitive: A1 - Approval brentuximab vedotin Sensitive : A1
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	denileukin diftitox Sensitive: A1 - Approval denileukin diftitox Sensitive : A1
ALK positive ALK positive	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	etoposide IV Sensitive: A2 - Guideline etoposide IV Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	cyclophosphamide oral Sensitive: A2 - Guideline cyclophosphamide oral Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	etoposide IV + cyclophosphamide oral Sensitive: A2 - Guideline etoposide IV + cyclophosphamide oral Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	bortezomib Sensitive: A2 - Guideline bortezomib Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	alemtuzumab Sensitive: A2 - Guideline alemtuzumab Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	pralatrexate Sensitive: A2 - Guideline pralatrexate Sensitive : A2
No biomarker No biomarker	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	RP6530 Sensitive: B - Late Trials RP6530 Sensitive : B
IL2RA expression IL2RA expression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	denileukin diftitox Sensitive: C1 - Off-label denileukin diftitox Sensitive : C1
PD-L1 overexpression PD-L1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	GB226 Sensitive: C3 – Early Trials GB226 Sensitive : C3
PD-1 overexpression PD-1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
RHOA mutation RHOA mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
IDH2 mutation IDH2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
TSC2 mutation TSC2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials copanlisib Sensitive : C3
TNFRSF8 positive TNFRSF8 positive	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	BV-ICE Sensitive: C3 – Early Trials BV-ICE Sensitive : C3
IL10-H IL10-H	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	CHOP Resistant: C3 – Early Trials CHOP Resistant : C3
RPS6 underexpression RPS6 underexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES